Promising pancreatic cancer combo trial halted early
NCT ID NCT04390763
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the experimental drugs NIS793 (with or without spartalizumab) to standard chemotherapy could help people with metastatic pancreatic cancer that had not been treated before. The trial enrolled 164 adults and aimed to see if the combinations slowed cancer growth better than chemo alone. However, the study was terminated early, so final results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Cente
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
Westmead, New South Wales, 2145, Australia
-
Novartis Investigative Site
Melbourne, Victoria, 3000, Australia
-
Novartis Investigative Site
Salzburg, 5020, Austria
-
Novartis Investigative Site
Vienna, A-1090, Austria
-
Novartis Investigative Site
Liège, 4000, Belgium
-
Novartis Investigative Site
Brno, Czech Republic, 656 53, Czechia
-
Novartis Investigative Site
Helsinki, FIN-00029, Finland
-
Novartis Investigative Site
Paris, 75475, France
-
Novartis Investigative Site
Toulouse, 31054, France
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Heidelberg, 69120, Germany
-
Novartis Investigative Site
Ulm, 89081, Germany
-
Novartis Investigative Site
Milan, MI, 20132, Italy
-
Novartis Investigative Site
Milan, MI, 20141, Italy
-
Novartis Investigative Site
Rozzano, MI, 20089, Italy
-
Novartis Investigative Site
Verona, VR, 37134, Italy
-
Novartis Investigative Site
Singapore, 119074, Singapore
-
Novartis Investigative Site
Singapore, 168583, Singapore
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
-
Novartis Investigative Site
Barcelona, Catalonia, 08036, Spain
-
Novartis Investigative Site
Madrid, 28050, Spain
-
Novartis Investigative Site
Sankt Gallen, 9007, Switzerland
-
Novartis Investigative Site
Zurich, 8091, Switzerland
-
Novartis Investigative Site
Taichung, 40447, Taiwan
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
Novartis Investigative Site
Oxford, OX3 7LE, United Kingdom
-
Sidney Kimmel CCC At JH
Baltimore, Maryland, 21231, United States
-
Univ of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15232, United States
-
Winship Cancer Institute
Atlanta, Georgia, 30322, United States